- Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approachStephen Wright
GW Pharma, Ltd, Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, UK
Trials 13:189. 2012..We report the results of an evidence-based statistical approach to exploring the possible impact of unblinding to a cannabis-based medicine (Sativex®) in people with muscle spasticity due to multiple sclerosis...
- Cannabinoid-based medicines for neurological disorders--clinical evidenceStephen Wright
GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wilts, UK
Mol Neurobiol 36:129-36. 2007..One of these, Sativex (GW Pharmaceuticals), was approved as a prescription medicine in Canada in 2005 and is currently under regulatory review in the EU...